Skip to content
    IART
    Earnings call· Jun 2026(Q2 FY26)

    INTEGRA LIFESCIENCES HOLDINGS Q2 FY26 earnings call IART

    Jul 29, 2026 Source

    Executive summary

    Integra LifeSciences Q2 FY26 — Strong Operational Execution and Reaffirmed Full-Year Outlook

    Integra LifeSciences delivered solid Q2 FY26 results, driven by improved operational execution and supply reliability, leading to an EPS beat. The company reaffirmed its full-year organic revenue and adjusted EPS guidance, leveraging cost savings and tariff favorability to offset anticipated higher interest expenses. Strategic initiatives, including the successful Primatrix relaunch and the upcoming Surgimend relaunch with its PMA strategy, are strengthening the foundation for sustainable long-term growth, despite some segment-specific headwinds.

    Highlights

    6

    • Adjusted EPS of $0.56, an increase of 24% compared to the prior year, exceeding the high end of guidance.

    • Revenue for the second quarter was $419 million, up $27 million sequentially and in line with May guidance.

    • Gross margin for the quarter was 61.3%, up approximately 60 basis points from 60.7% in the prior year.

    • Adjusted EBITDA margin was 18.7%, up approximately 160 basis points versus 17.1% in Q2 2025.

    • Operating cash flow totaled $22.8 million in the second quarter, compared to $8.9 million in the prior year.

    • Primatrix relaunch revenues have recovered to slightly more than 50% of pre-recall levels, increasing sequentially.

    Concerns

    4

    • Tissue reconstruction revenues were down 1.9% on a reported basis and 2% on an organic basis compared to the prior year.

    • ENT revenue declined low single digits, reflecting continued pressures in sinus balloons.

    • Micromatrix declined in the quarter versus the prior year due to increased competition from new entrants.

    • Higher interest expense is anticipated in the second half of 2026 due to the current rate environment and a potential refinancing.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year organic revenue growth
    0.8% to 3.3%
    high materiality
    High
    Full-year reported revenue
    $1.654 billion to $1.695 billion
    high materiality
    Medium
    Full-year adjusted EPS
    $2.40 to $2.50
    high materiality
    High
    Q3 revenue
    $410 million to $425 million
    medium materiality
    High
    Q3 adjusted EPS
    $0.53 to $0.61
    medium materiality
    High
    Gross margin expansion
    60 basis points
    medium materiality
    High
    Adjusted EBITDA margin expansion
    100 basis points
    medium materiality
    High
    Total leverage ratio
    approach upper end of 2.5 to 3.5 times
    high materiality
    High
    Operating cash flow improvement
    approximate $150 million improvement
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Specialty Surgery
    Performance driven by improved supply reliability in neurosurgery. Capital equipment sales saw mixed results, and ENT faced continued pressures.
    Organic growth: 1.6%Global neurosurgery organic growth: 1.9% (driven by Sirtis Plus, KUSA, Bactocele)Capital equipment sales: down ~1% (KUSA double-digit growth offset by smaller ticket items)Instruments growth: low single digitsENT revenue: declined low single digits (Microfrance ENT instruments growth offset by sinus balloons pressure)International sales growth: low single digits
    		$309.3 million1.7% reported——
    Tissue Reconstruction
    Decline primarily due to tough prior-year comps for Integra Skin and increased competition for Micromatrix. Primatrix relaunch showing strong momentum.
    Organic growth: -2%Wound reconstruction: approximately flat for H1 2026 vs 2025Integra Skin: grew sequentially Q2 vs Q1, but down YoY (due to Q2 2025 backorder clearance)Micromatrix: declined YoY (increased competition)Private label sales growth: 4.7%International sales growth: low single digits (driven by Integra Skin)
    		$109.5 million-1.9% reported——

    Operational metrics

    12
    Adjusted EPS
    $0.56up 24% YoY
    Q2 FY26

    Above the high end of guidance, driven by improved operating execution and favorable tariff dynamics.

    Gross margin
    61.3%up 60 bps YoY
    Q2 FY26

    Reflecting efficiencies achieved across manufacturing operations and lower remediation spending.

    Adjusted EBITDA margin
    18.7%up 160 bps YoY
    Q2 FY26

    Reflecting benefits of gross margin drivers and contributions from margin improvement initiatives.

    Capital expenditures
    $12.3 million
    Q2 FY26

    Investment in capital assets.

    Net debt
    $1.6 billion
    as of June 30

    Current net debt balance.

    Total liquidity
    $496 million
    as of June 30

    Includes $274 million in cash and short-term investments, with the remainder available under revolving credit facility.

    Cash and short-term investments
    $274 million
    as of June 30

    Part of total liquidity.

    Cost savings from initiatives
    $25 million to $30 million
    FY26

    Expected savings from transformation initiatives.

    Incremental annualized cost savings
    $10 million to $15 million
    FY27

    Additional annualized savings expected from initiatives in 2027.

    Primatrix relaunch revenue recovery
    slightly more than 50%of pre-recall levels
    approx. 9 months into relaunch

    Revenues continue to increase sequentially quarter over quarter.

    Surgimend historical performance
    $40 million
    historical

    Reference for expected modest recovery post-relaunch.

    Surgimend expected recovery
    50%of historical performance
    post-relaunch

    Expected modest recovery, similar to Primatrix.

    Industry KPIs

    8
    MetricValueDetails
    Tariff impact$0.05USD per share
    New product launch rampslightly more than 50%%
    Procedure volume growthconsistent
    FCF conversion leverage guidance24%%
    Installed base system placementsdown ~1%%
    Segment franchise organic growth1.6%%
    Sales force commercial capacity buildNo real increase expected
    Pivotal trial clinical evidence milestonesApprovable decision received

    Deals & partnerships

    1
    SEIAFinal milestone payment related to prior acquisition$11 million

    Final milestone payment for the SEIA acquisition was made in Q2 2026.

    Risks & headwinds

    4
    Higher interest expenseH2 2026

    Expected in second half of 2026

    Mitigation: Expected to be offset by tariff favorability in 2026 and ongoing operational improvements and cost savings initiatives in 2027.

    Flooding at Cincinnati manufacturing siteQ3 2026

    Operational disruption

    Mitigation: No material impact on revenue or EPS guidance for 2026 expected, due to inventory available at distribution centers, secondary supply sources, and insurance coverage.

    Reimbursement pressures in sinus balloonsOngoing

    Low single-digit decline in ENT revenue

    Mitigation: Focus on innovation in navigated systems and e-station tubes to drive long-term growth in ENT.

    Increased competition for MicromatrixQ2 FY26

    Decline in Micromatrix revenue

    Mitigation: Not explicitly stated, but company emphasizes breadth of portfolio and market leadership in complex wound reconstruction.

    What to watch in Q3 FY26

    5

    Surgimend relaunch progress

    Q4 FY26
    CurrentManufacturing restarted, building inventory
    TargetPhased Q4 relaunch with sufficient inventory

    Why it matters

    Successful relaunch of Surgimend is a key operational milestone and critical for future growth in tissue reconstruction.

    Our near-term focus is building inventory to support a phased and disciplined Q4 relaunch with sufficient inventory expected for the launch.

    Q&A highlights

    10

    Why was full-year EPS guidance held intact despite a Q2 EPS beat of $0.08, including $0.03 organic outperformance?

    The Q2 EPS beat was primarily driven by $0.05 per share of tariff favorability, in addition to stronger operational execution. The tariff upside is now being used to mitigate an expected increase in interest expense in the second half due to a planned refinancing, rather than flowing through to full-year guidance.

    “In addition, though, we saw tariff favorability of about five cents per share. So that's what drove us above the high end of our guide for the quarter. And to your point, in the second half, what we are now doing is that the upside that we saw from tariff favorability, which we had communicated in May, we have right-sized our tariff estimates or assumptions, continue to believe our tariff exposure for the year will be about 10 cents. And what we had as protection for any additional tariff changes, we are now using to mitigate an expectation of higher interest expense in the second half as a result of a planned refinancing transaction.”

    asked by Anton · answered by Leah Knight

    2 min read5 chapters

    Detailed Narrative

    01

    Operational Improvements and Cost Savings

    Integra LifeSciences is realizing benefits from broader operational changes, including better alignment of commercial organization, operating model, and transformation initiatives. These efforts have contributed to cost savings in Q2 FY26 and are expected to drive further margin improvement in coming years. The company projects $25 million to $30 million in cost savings for FY26, with an additional $10 million to $15 million annually in FY27 from these initiatives.

    02

    Tissue Reconstruction Strategy and Relaunches

    The company maintains a strong market position in tissue reconstruction, anchored by Integra Skin. The relaunch of Primatrix is progressing exceptionally well, with revenues recovering to over 50% of pre-recall levels within nine months. Manufacturing at the Braintree facility has successfully restarted, building inventory for the phased Q4 2026 relaunch of Surgimend. The dual PMA strategy for Surgimend and Durazorb aims to expand their labels for implant-based breast reconstruction, with approvals expected in 2027.

    03

    Capital Allocation and De-leveraging

    De-leveraging remains the top capital allocation priority. Integra exited Q2 FY26 with a total leverage of 4.1 times, down from 4.5 times at year-end, and expects to approach the upper end of its 2.5 to 3.5 times target range by the end of 2026. The company is evaluating opportunities to optimize its capital structure and expects to refinance outstanding bank debt in H2 2026, anticipating higher interest expenses to be offset by tariff favorability and operational improvements.

    04

    ENT Business and Innovation Focus

    The ENT segment experienced a low single-digit decline in Q2 FY26, with growth in Microfrance ENT instruments offset by ongoing pressures in sinus balloons due to reimbursement headwinds. The company's focus for long-term growth in ENT is on innovation, particularly in navigated systems and e-station tubes, to drive future expansion.

    05

    Supply Chain and Manufacturing Resilience

    Improvements in supply reliability have been significant, enabling the commercial organization to be more proactive. A recent flooding event at the Cincinnati manufacturing site is not expected to materially impact 2026 revenue or EPS guidance, thanks to available inventory, secondary supply sources, and insurance coverage. The Braintree facility's successful restart and inventory build for Surgimend highlight strengthening operational performance.

    AI-generated summary of the company’s earnings call. Not investment advice.